Loading…
Bio-Techne Corporation is projected to rise to $92.42 by 2027, a +28% move from its current price of $72.03. TECH is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $70.99 | $72.07 | $73.16 | +0.05% |
| Aug 2 | $70.58 | $72.10 | $73.66 | +0.10% |
| Aug 3 | $70.28 | $72.14 | $74.05 | +0.15% |
| Aug 4 | $70.03 | $72.17 | $74.38 | +0.20% |
| Aug 5 | $69.81 | $72.21 | $74.69 | +0.25% |
| Aug 6 | $69.62 | $72.24 | $74.97 | +0.30% |
| Aug 7 | $69.45 | $72.28 | $75.23 | +0.35% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $69.45 | $72.28 | $75.23 | +0.35% |
| Week 2 | $68.55 | $72.53 | $76.75 | +0.69% |
| Week 3 | $67.92 | $72.78 | $78.00 | +1.04% |
| Week 4 | $67.43 | $73.03 | $79.11 | +1.39% |
| Week 5 | $67.03 | $73.29 | $80.13 | +1.75% |
| Week 6 | $66.69 | $73.54 | $81.10 | +2.10% |
| Week 7 | $66.40 | $73.80 | $82.02 | +2.45% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.
The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids.
The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Bio-Techne Corporation (TECH) is a healthcare company that develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
The stock trades at $71.60 per share and has a market cap of $11.16B. It ranks 830.
The current price outlook is supported by the forecast, with a path that starts around the current level in 2026 (avg $71.60) and accelerates into a bullish long-term trajectory, with later years showing strong upside. By 2030 the avg is $169.97 and by 2050 the avg is $1,069.97, with max values reaching $231.53 in 2030 and $1,749.06 in 2050. The forecast also shows growing ROIs, from 0 in 2026 to 1394.4 by 2050, with a bullish sentiment across the longer horizon.
A major floor 39.9% below — a decisive break under it would weaken the trend.
The nearest floor, 23.6% below — buyers have tended to step in here.
Price is pressing into resistance (0.1% away) — a breakout level to watch.
A major ceiling 15.9% above — clearing it would confirm fresh momentum.
Key TECH support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TECH market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $71.87 | Buy | $71.93 | Buy |
| MA 10 | $71.83 | Buy | $71.70 | Buy |
| MA 20 | $71.50 | Buy | $70.20 | Buy |
| MA 50 | $61.81 | Buy | $64.75 | Buy |
| MA 100 | $57.31 | Buy | $61.11 | Buy |
| MA 200 | $59.57 | Buy | $59.59 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 74.33 | Sell |
| Stoch RSI (14) | 26.08 | Neutral |
| CCI (20) | 98.66 | Neutral |
| Williams %R (14) | -10.11 | Info |
| MACD (12,26,9) | -0.64 | Sell |
| ROC (12) | 1.12 | Buy |
| Bollinger %B (20,2) | 0.81 | Neutral |
| Stochastic %K (14) | 89.89 | Sell |
| TRIX (15) | 0.75 | Buy |
| Awesome (5,34) | 4.57 | Buy |
| Ultimate (7,14,28) | 72.49 | Sell |
| Momentum (10) | 0.26 | Buy |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 72.04 | Sell |
| ADX (14) | 45.28 | Buy |
| ATR (14) | 0.52 | Info |
The 30-day technical picture is NEUTRAL with RSI (14) at 70. Near-term momentum is balanced around key levels.
The 50-day simple moving average sits at $59.12 (SMA50) and the 200-day simple moving average sits at $59.27 (SMA200). Support is indicated at $52.50 and resistance at $72.12. The 30-day price range spans from $63.77 to $80.39, illustrating a range-bound tendency in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $43.30 | $72.03 | $94.17 | 0% | Neutral | |
| $75.78 | $92.42 | $117.78 | +28% | Bullish | |
| $85.13 | $105.80 | $138.54 | +47% | Bullish | |
| $110.88 | $139.96 | $187.21 | +94% | Bullish | |
| $130.87 | $167.43 | $228.03 | +132% | Bullish | |
| $134.81 | $174.59 | $241.56 | +142% | Bullish | |
| $151.22 | $198.05 | $277.94 | +175% | Bullish | |
| $164.11 | $217.20 | $308.78 | +202% | Bullish | |
| $178.23 | $238.25 | $342.76 | +231% | Bullish | |
| $217.24 | $293.16 | $426.47 | +307% | Bullish | |
| $303.40 | $427.06 | $651.13 | +493% | Bullish | |
| $675.39 | $1,019.64 | $1,666.68 | +13.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $43.30 | $72.03 | $83.84 | +0.00% |
| August 2026 | $62.38 | $72.73 | $86.43 | +0.97% |
| September 2026 | $64.26 | $75.35 | $90.38 | +3.60% |
| October 2026 | $64.57 | $76.07 | $91.92 | +0.95% |
| November 2026 | $63.84 | $75.50 | $91.78 | -0.76% |
| December 2026 | $64.93 | $77.04 | $94.17 | +2.05% |
Click any year to see its month-by-month TECH forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, TECH is projected to trade between $43.30 and $94.17, averaging $72.03 — a potential gain of 0% from today's $72.03. A consolidation phase looks the most probable path here.
Bio-Techne Corporation's 2027 outlook centres on $92.42, within a $75.78 to $117.78 range. That is up +28% on the projected 2026 average. That marks a +28% change versus current levels. Momentum favours further upside here.
By 2028, TECH could reach as high as $138.54, with a base case around $105.80 and support toward $85.13 — roughly +47% from $72.03. Buyers look set to stay in control over this stretch.
Expect TECH to range from $110.88 to $187.21 through 2029. The $139.96 average target implies a +94% move from current prices. That is up +32% on the projected 2028 average. Momentum favours further upside here.
The TECH price prediction for 2030 points to an average of $167.43 (low $130.87, high $228.03) — a potential gain of +132% on today's $72.03. Buyers look set to stay in control over this stretch.
In 2031, TECH is projected to trade between $134.81 and $241.56, averaging $174.59 — a potential gain of +142% from today's $72.03. That is up +4% on the projected 2030 average. Momentum favours further upside here.
Bio-Techne Corporation's 2032 outlook centres on $198.05, within a $151.22 to $277.94 range. That is up +13% on the projected 2031 average. That marks a +175% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, TECH could reach as high as $308.78, with a base case around $217.20 and support toward $164.11 — roughly +202% from $72.03. Momentum favours further upside here.
Expect TECH to range from $178.23 to $342.76 through 2034. The $238.25 average target implies a +231% move from current prices. That is up +10% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The TECH price prediction for 2035 points to an average of $293.16 (low $217.24, high $426.47) — a potential gain of +307% on today's $72.03. Momentum favours further upside here.
In 2040, TECH is projected to trade between $303.40 and $651.13, averaging $427.06 — a potential gain of +493% from today's $72.03. That is up +46% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Bio-Techne Corporation's 2050 outlook centres on $1,019.64, within a $675.39 to $1,666.68 range. That is up +139% on the projected 2040 average. That marks a +13.2x change versus current levels. Momentum favours further upside here.
Investing $1,000 in TECH today (≈ 13.883104 TECH) could be worth
$14,155.78
+$13,155.78 (+1316%) by 2050 · US Dollar
Based on the average projected TECH price of $1,019.64 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TECHwould be worth at today's price.
$1,000 invested in TECH on Jul 30, 2025 (≈ 17.32802 TECH) would be worth
$1,248.14
+$248.14 (+24.8%) today · 1.25× · US Dollar
Based on a TECH entry price of $57.71 vs. today's $72.03.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $71.77 | $1,003.62 | +0.4% |
| 1 month ago | $70.65 | $1,019.53 | +2.0% |
| 3 months ago | $55.02 | $1,309.16 | +30.9% |
| 6 months ago | $64.09 | $1,123.89 | +12.4% |
| 1 year ago | $57.71 | $1,248.14 | +24.8% |
| All time (5.0y) ago | $121.43 | $593.16 | -40.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TECH forecast.
Our base-case forecast reaches $140.00 around 2030.
Implied market cap at $140.00: $21.81B
The multi-year forecast shows a bullish trajectory through 2050, with the average price rising from 2027's $92.57 to 2050's $1,069.97 and the long-run max climbing to $1,749.06. This path is accompanied by escalating ROIs, from 29.3 in 2027 to 1,394.4 by 2050, and a sustained BULLISH sentiment.
Key milestones include 2030 with an avg of $169.97 and ROI 137.4, 2040 with an avg of $443.82 and ROI 519.9, and 2050 with an avg of $1,069.97 and ROI 1394.4. The corresponding max prices rise to $231.53 (2030), $676.75 (2040), and $1,749.06 (2050). These are estimates and not guarantees; actual results may differ.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $169.97, with a low of $132.84 and a high of $231.53. The projected ROI is 137.4 and the sentiment is BULLISH.
From 2027 onward, the forecast is BULLISH with rising averages and ROIs (e.g., 29.3 in 2027, 49.4 in 2028, 98.9 in 2029, 137.4 in 2030, 148 in 2031, 183.7 in 2032, 211.2 in 2033, 242.1 in 2034, 324.3 in 2035, 519.9 in 2040, and 1394.4 in 2050). The 2026 forecast is NEUTRAL.
Yes. The forecast shows a 2050 max of $1,749.06 and an average of $1,069.97, which exceed $1,000, with the 2040 max at $676.75 and the 2030 max at $231.53.
RSI(14) is 70. The 50-day SMA is $59.12 and the 200-day SMA is $59.27. Support is at $52.50 and resistance at $72.12. The 30-day price range is $63.77 to $80.39.
2040: avg $443.82, max $676.75, ROI 519.9, sentiment BULLISH. 2050: avg $1,069.97, max $1,749.06, ROI 1394.4, sentiment BULLISH.
Bio-Techne Corporation Community Discussion
0Share your Bio-Techne Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.